Clinical trial
Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma
NCT00424515 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00424515 |
|---|---|
| Title | Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma |
| Official title | A Phase II Study of Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma and Melanomas That Arise on Chronically Sun Damaged Skin. |
| Acronym | BUS255 |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Novartis Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Mucosal Melanoma, Acral/Lentiginous Melanoma, Chronically Sun Damaged Melanomas |
| Intervention type | Drug |
| Interventions | Imatinib |
| Enrollment | 24 |
| Start date | Jul 1, 2006 |
| Primary completion | Jul 1, 2011 |
| Completion | Jul 1, 2011 |
| First posted | Jan 19, 2007 |
| Last update posted | Dec 8, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: